DUBLIN, Ireland , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today ...
Patients treated with NOCTIVA were three times more likely to report no difficulty getting enough sleep and five times more likely to report no bother due to nocturia DUBLIN, Ireland , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Avadel ...
We are a global pharmaceutical company, proud to be unique in our space as experts in the development and commercialization of safe, novel products that address unmet medical needs through improved dosing and by ensuring the safety and efficacy of our products and product candidates.
Whether we are seeking FDA approval of commonly used drugs, acquiring new assets or utilizing our innovative technologies to change the method of administering medication, Avadel approaches every product with the patient in mind.